Correlations between immunohistochemical and radiographic pharmacodynamic parameters. (A-C) Percent change in phospho-Rb on PD0332991 treatment compared with the percentage change in Ki-67, the percentage decrease in summed FLT SUV_max, and time to progression. (D-E) Percent change in Ki-67 expression on PD033291 treatment compared with the percentage decrease in summed FLT SUV_max and time to progression. (F) Kaplan-Meier analysis of time to progression among patients who achieved > 50% reduction in Ki-67 (all with ≥ 87.5% decrease) on PD0332991 compared with other patients who achieved a ≤ 50% decrease.